Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.nektar.com
Nektar Therapeutics News Releases
Get the latest updates from Nektar Therapeutics News Releases directly as they happen.
Follow now 74 followers
Latest posts
Last updated 6 days ago
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
6 days ago
SAN FRANCISCO , Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
about 1 month ago
Study met primary and key secondary endpoints at week 16 in patients...
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
about 2 months ago
SAN FRANCISCO , Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics to Participate in Two Investor Conferences in September
about 2 months ago
SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
3 months ago
SAN FRANCISCO , Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
3 months ago
SAN FRANCISCO , Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets
3 months ago
SAN FRANCISCO , July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets
3 months ago
SAN FRANCISCO , July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata
3 months ago
SAN FRANCISCO , July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata
3 months ago
SAN FRANCISCO , July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
4 months ago
SAN FRANCISCO , July 2, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics Announces Pricing of $100 Million Public Offering
4 months ago
SAN FRANCISCO , July 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...